The RNA Cure?
It is being hailed as one of the biggest advances in biology in decades, one that could eventually lead to drugs for a wide range of diseases, from cancer to diabetes to AIDS. And one startup, Cambridge, MA-based Alnylam Pharmaceuticals, is in a particularly strong position to transform it into new pharmaceuticals.
In 1998, scientists discovered that RNA interference (RNAi)-a natural process in which small, double-stranded RNA molecules shut down the activity of particular genes-takes place in animals. For biomedical researchers, the implications were obvious; if you could selectively block genes involved in a disease, you could, in theory at least, stop it. Founded in 2002 by some of the pioneers of RNA interference research, Alnylam aims to synthesize small RNA molecules that could become the basis for a broad class of new drugs. So far, Alnylam has focused on cancer and metabolic diseases like diabetes. Its ambitious goal is to have a drug candidate in human testing by the end of 2005.
Keep Reading
Most Popular

These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.

Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.